{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.2","value":"-4.8"}]}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"14.4","value":"0.0"}]}],"title":"Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.2","value":"-14.9"}]}],"title":"End of treatment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"HRQoL was assessed with the FACT-L questionnaire, a validated instrument for determining lung cancer HRQoL. The 36-item questionnaire includes 4 domains: Physical, functional, emotional, and social/family well-being, and a lung cancer-specific subscale. The FACT-L total score ranges from 1 to 136. Lower scores (negative change from baseline) demonstrate impaired HRQoL.","dispersionType":"Standard Deviation","groups":[{"description":"Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (bid, bis in die) X 28 day cycles","id":"OG000","title":"Sorafenib"}],"paramType":"MEAN","populationDescription":"The analysis population for the intent to treat (ITT) and safety analyses consisted of 52 subjects who received at least 1 treatment and had their disease re-evaluated. Of the 52 treated subjects, 50 subjects completed the FACT-L at baseline (screening) and post-treatment.","reportingStatus":"POSTED","timeFrame":"From first patient first treatment until date of last efficacy data collection (study period up to 62 weeks). HRQoL assessed at baseline (BL), end of treatment Cycles 2 and 4, and at end of treatment","title":"Change From Baseline of Health-Related Quality of Life (HRQOL) Score Assessed at Cycle 2, Cycle 4, and End of Treatment (EOT)","type":"SECONDARY","unitOfMeasure":"scores on a scale"}